Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: Pre- and postsynaptic mechanisms

Neuropsychopharmacology

Volumn 31, Issue 9, 2006, Pages 1967-1981

  Perreault, Melissa L ^a   Graham, Dawn ^a   Bisnaire, Liane ^a   Simms, Jennifer ^a   Hayton, Scott ^a   Szechtman, Henry ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Chronic drug treatment; Components of sensitization; Dose response curves; Kappa opioid dopamine receptor coactivation; Oppositional D1 D2 interaction; U69593

Indexed keywords

DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; KAPPA OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; QUINPIROLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BEHAVIORAL SENSITIZATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION;

ALGORITHMS; ANALGESICS; ANIMALS; BENZENEACETAMIDES; DATA INTERPRETATION, STATISTICAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MALE; MOTOR ACTIVITY; PYRROLIDINES; QUINPIROLE; RATS; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, OPIOID, KAPPA; RECEPTORS, PRESYNAPTIC; SYNAPSES;

EID: 33747341585     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300938     Document Type: Article

References (73)

1. Acri JB, Thompson AC, Shippenberg T (2001). Modulation of preand postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse 39: 343-350.
2. Antelman SM, Chiodo LA (1983). Amphetamine as a stressor. In: Creese I (ed). Stimulants: Neurochemical, Behavioral and Clinical Perspectives. Raven Press: New York. pp 269-299.
3. Baker TB, Tiffany ST (1985). Morphine tolerance as habituation. Psychol Rev 92: 78-108.
4. Castro R, Abreu P, Calzadilla CH, Rodriguez M (1985). Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval. Psychopharmacology (Berl) 85: 333-339.
5. Centonze D, Usiello A, Gubellini P, Pisani A, Borrelli E, Bernardi G et al (2002). Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology 27: 723-726.
6. Clark D, Hjorth S, Carlsson A (1985). Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62: 171-207.
7. Collins SL, D'Addario C, Izenwasser S (2001a). Effects of kappaopioid receptor agonists on long-term cocaine use and dopamine neurotransmission. Eur J Pharmacol 426: 25-34.
8. Collins SL, Gerdes RM, D'Addario C, Izenwasser S (2001b). Kappa opioid agonists alter dopamine markers and cocaine-stimulated locomotor activity. Behav Pharmacol 12: 237-245.
9. Dall'Olio R, Gaggi R, Voltattorni M, Tanda O, Gandolfi O (2002). Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors. Behav Pharmacol 13: 633-638.
10. Daly SA, Waddington JL (1992). Two directions of dopamine D1/D2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists. Eur J Pharmacol 213: 251-258.
11. Di Chiara G, Porceddu ML, Vargiu L, Argiolas A, Gessa GL (1976). Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264: 564-567.
12. Di Chiara G, Porceddu ML, Vargiu L, Gessa GL (1978). Stimulation of 'regulatory' dopamine receptors by bromocriptine (CB-154). Pharmacology 16(Suppl 1): 135-142.
13. Eilam D, Clements KV, Szechtman H (1991). Differential effects of D1 and D2 dopamine agonists on stereotyped locomotion in rats. Behav Brain Res 45: 117-124.
14. Eilam D, Szechtman H (1989). Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161: 151-157.
15. Eilam D, Szechtman H (2005). Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: an ethological approach to the form of compulsive rituals. CNS Spectr 10: 191-202.
16. Eilam D, Talangbayan H, Canaran G, Szechtman H (1992). Dopaminergic control of locomotion, mouthing, snout contact, and grooming: opposing roles of D1 and D2 receptors. Psychopharmacology (Berl) 106: 447-454.
17. Einat H, Einat D, Allan M, Talangbayan H, Tsafnat T, Szechtman H (1996). Associational and nonassociational mechanisms in locomotor sensitization to the dopamine agonist quinpirole. Psychopharmacology (Berl) 127: 95-101.
18. Harkin A, Kelly JP, Frawley J, O'Donnell JM, Leonard BE (2000). Test conditions influence the response to a drug challenge in rodents. Pharmacol Biochem Behav 65: 389-398.
19. Henry DJ, Hu XT, White FJ (1998). Adaptations in the mesoaccumbens dopamine system resulting from repeated administration of dopamine D1 and D2 receptor-selective agonists: relevance to cocaine sensitization. Psychopharmacology (Berl) 140: 233-242.
20. Hinson RE, Siegel S (1983). Anticipatory hyperexcitability and tolerance to the narcotizing effect of morphine in the rat. Behav Neurosci 97: 759-767.
21. Imperato A, Tanda G, Frau R, Di Chiara G (1988). Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J Pharmacol Exp Ther 245: 257-264.
22. Izenwasser S, Acri JB, Kunko PM, Shippenberg T (1998). Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse 30: 275-283.
23. Kalivas PW, Stewart J (1991). Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16: 223-244.
24. Kelland MD, Freeman AS, Lewitt PA, Chiodo LA (1990). Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study. J Pharmacol Exp Ther 255: 276-284.
25. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G et al (1998). Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18: 3470-3479.
26. Kelsey JE, Carlezon Jr WA (2002). Prior experience with bromocriptine in the home cage attenuates locomotor sensitization in rats. Behav Brain Res 134: 1-8.
27. Khan ZU, Mrzljak L, Gutierrez A, de la CA, Goldman-Rakic PS (1998). Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 95: 7731-7736.
28. King GR, Xiong Z, Douglas S, Lee TH, Ellinwood EH (1999). The effects of continuous cocaine dose on the induction of behavioral tolerance and dopamine autoreceptor function. Eur J Pharmacol 376: 207-215.
29. Koeltzow TE, Austin JD, Vezina P (2003). Behavioral sensitization to quinpirole is not associated with increased nucleus accumbens dopamine overflow. Neuropharmacology 44: 102-110.
30. Koob GF, Le Moal M (1997). Drug abuse: hedonic homeostatic dysregulation. Science 278: 52-58.
31. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P et al (2003a). Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 100: 4305-4309.
32. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P et al (2003b). Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 100: 4305-4309.
33. Lindgren N, Xu ZQ, Herrera-Marschitz M, Haycock J, Hokfelt T, Fisone G (2001). Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur J Neurosci 13: 773-780.
34. Lomanowska A, Gormley S, Szechtman H (2004). Presynaptic stimulation and development of locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 77: 617-622.
35. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR et al (2002). Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301: 1166-1178.
36. Muller P, Seeman P (1979). Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics. Eur J Pharmacol 55: 149-157.
37. Muscat R, Iravani MM, Kruk ZL (1996). The role of ventral tegmental dopamine neurons in locomotor sensitization following quinpirole or (+)-amphetamine: ex vivo voltammetric evidence. Neuroscience 75: 1175-1184.
38. Onali P, Olianas MC (1989). Involvement of adenylate cyclase inhibition in dopamine autoreceptor regulation of tyrosine hydroxylase in rat nucleus accumbens. Neurosci Lett 102: 91-96.
39. Pitts DK, Wang L, Kelland MD, Freeman AS, Chiodo LA (1995). Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole. J Pharmacol Exp Ther 275: 412-421.
40. Richtand NM, Woods SC, Berger SP, Strakowski SM (2001). D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25: 427-443.
41. Robertson GS, Robertson HA (1986). Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats. Brain Res 384: 387-390.
42. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396: 157-198.
43. Rouge-Pont F, Usiello A, Benoit-Marand M, Gonon F, Piazza PV, Borrelli E (2002). Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J Neurosci 22: 3293-3301.
44. Schoffelmeer AN, Hogenboom F, Mulder AH (1997). Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum. Br J Pharmacol 122: 520-524.
45. Seamans JK, Yang CR (2004). The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74: 1-58.
46. Segal DS, Schuckit MA (1983). Animal models of stimulantinduced psychosis. In: Creese I (ed). Stimulants: Neurochemical, Behavioral and Clinical Perspectives. New York: Raven Press. pp 131-167.
47. Segal DS, Weinberger SB, Cahill J, McCunney SJ (1980). Multiple daily amphetamine administration: behavioral and neurochemical alterations. Science 207: 905-907.
48. Shilliam CS, Heidbreder CA (2003). Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. Eur J Pharmacol 477: 113-122.
49. Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA (2001). Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann N Y Acad Sci 937: 50-73.
50. Skirboll LR, Grace AA, Bunney BS (1979). Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 206: 80-82.
51. Spanagel R, Herz A, Shippenberg TS (1992). Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2046-2050.
52. Starke K (1981). Presynaptic receptors. Annu Rev Pharmacol Toxicol 21: 7-30.
53. Starr BS, Starr MS (1986). Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Implications for the roles of D1 and D2 receptors. Neuropharmacology 25: 455-463.
54. Steiner H, Gerfen CR (1998). Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp Brain Res 123: 60-76.
55. Svingos AL, Chavkin C, Colago EE, Pickel VM (2001). Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42: 185-192.
56. Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM (1994a). Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 48: 921-928.
57. Szechtman H, Eckert MJ, Tse WS, Boersma JT, Bonura CA, McClelland JZ et al (2001). Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. BMC Neurosci 2: 4.
58. Szechtman H, Sulis W, Eilam D (1998). Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112: 1475-1485.
59. Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D (1994b). Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism (published erratum appears in Psychopharmacology (Berl) 1994 Sep;116(1):124). Psychopharmacology (Berlin) 115: 95-104.
60. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H (1997). Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology (Berlin) 134: 193-200.
61. Szumlinski KK, Goodwill AM, Szechtman H (2000). Locomotor sensitization to quinpirole in rats: effects of drug abstinence and sex. Psychopharmacology (Berlin) 152: 304-311.
62. Takekoshi K, Ishii K, Kawakami Y, Isobe K, Nakai T (2000). Kappa-opioid inhibits catecholamine biosynthesis in PC12 rat pheochromocytoma cell. FEBS Lett 477: 273-277.
63. Tizabi Y, Louis VA, Taylor CT, Waxman D, Culver KE, Szechtman H (2002). Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol Psychiatry 51: 164-171.
64. Trantham-Davidson H, Neely LC, Lavin A, Seamans JK (2004). Mechanisms underlying differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J Neurosci 24: 10652-10659.
65. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M et al (2000). Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408: 199-203.
66. Van Hartesveldt C, Cottrell GA, Potter T, Meyer ME (1992). Effects of intracerebral quinpirole on locomotion in rats. Eur J Pharmacol 214: 27-32.
67. Van Hartesveldt C, Meyer ME, Potter TJ (1994). Ontogeny of biphasic locomotor effects of quinpirole. Pharmacol Biochem Behav 48: 781-786.
68. Vanderschuren LJ, Schoffelmeer AN, Mulder AH, de Vries TJ (1999). Dopaminergic mechanisms mediating the long-term expression of locomotor sensitization following pre-exposure to morphine or amphetamine. Psychopharmacology (Berl) 143: 244-253.
69. Vezina P, Giovino AA, Wise RA, Stewart J (1989). Environment-specific cross-sensitization between the locomotor activating effects of morphine and amphetamine. Pharmacol Biochem Behav 32: 581-584.
70. Wang Y, Xu R, Sasaoka T, Tonegawa S, Kung MP, Sankoorikal EB (2000). Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J Neurosci 20: 8305-8314.
71. White FJ, Wang RY (1986). Electrophysiological evidence for the existence of both D-1 and D-2 dopamine receptors in the rat nucleus accumbens. J Neurosci 6: 274-280.
72. Wise RA, Leeb K (1993). Psychomotor-stimulant sensitization: a unitary phenomenon? Behav Pharmacol 4: 339-349.
73. You ZB, Herrera-Marschitz M, Terenius L (1999). Modulation of neurotransmitter release in the basal ganglia of the rat brain by dynorphin peptides. J Pharmacol Exp Therap 290: 1307-1315.